Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 205-213

  Aronow, Herbert D ^a,c   Dutro, Michael P ^b   Kuznik, Andreas ^b   Cwengros, James ^b  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c Michigan Heart PC   (United States)

Author keywords

Cardiovascular diseases; Dyslipidemia; Managed care; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; EXERCISE TEST; FEMALE; HEALTH CARE UTILIZATION; HEART CATHETERIZATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; TOBACCO DEPENDENCE; TRANSIENT ISCHEMIC ATTACK; HEALTH INSURANCE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; EVIDENCE-BASED MEDICINE; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH; MALE; MEDICARE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 64249094798     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802611828     Document Type: Article

References (41)

1. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002.JAMA2005;294:1773-1781
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171 (Pubitemid 46226160)
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278 (Pubitemid 41416582)
4. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696 (Pubitemid 39140624)
5. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435 (Pubitemid 40471450)
8. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080 (Pubitemid 38541684)
9. Cannon CP, Braunwald MD, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504 (Pubitemid 38477774)
10. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
11. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313 (Pubitemid 44833354)
12. Messerli FH, Pinto L, Tang SSK, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy - a metaanalysis. Am J Cardiol 2008;101:319-325 (Pubitemid 351162960)
13. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: 227-239 (Pubitemid 38924592)
14. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000;14:83-90 (Pubitemid 30110439)
15. Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004;10:926-932 (Pubitemid 40040889)
16. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004;10:163-170 (Pubitemid 38332390)
17. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (5 55 years) men and women. Eur Heart J 2002;23:528-535
18. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64
19. Foody JM, Joyce AT, Rudolph AE, et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205 (Pubitemid 351834719)
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421
21. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652
22. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:I-IV, S1-91
23. Dutro MP, Gerthoffer TD, Peterson ED, et al. Treatment of hypertension and dyslipidemia or their combination among US managed-care patients. J Clin Hypertens (Greenwich) 2007;9:684-691
24. Dutro M, Koo YH, Koren AT, et al. Heart failure and managed care: Clinical characteristics and quality of drug therapy. Drug Benefit Trends 2005;17:571-580 (Pubitemid 44713282)
25. Raymond CB, Morgan SG, Katz A, et al. A population-based analysis of statin utilization in British Columbia. Clin Ther 2007;29:2107-2119 (Pubitemid 350218117)
26. Farahani P, Levine M, Gaebel K, et al. Exploring patient demographic and clinical characteristics associated with lipidlowering pharmacotherapy use in primary care. Clin Invest Med 2007;30:E63-9 (Pubitemid 47535694)
27. Kannel WB. Hypertensive risk assessment: cardiovascular risk factors and hypertension. J Clin Hypertens (Greenwich) 2004; 6:393-399
28. O'Meara JG, Kardia SL, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004;164:1313-1318 (Pubitemid 38828882)
29. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189 (Pubitemid 43076437)
30. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204-208 (Pubitemid 43996906)
31. Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693-700 (Pubitemid 30433239)
32. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572 (Pubitemid 37430158)
33. American Diabetes Association. Clinical Practice Recommendations 2007. Diabetes Care 2007;30(Suppl 1)
34. Smith SC Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
35. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235
36. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445 (Pubitemid 41627921)
37. Candrilli SD, Kuznik A, Rudolph AE. The prevalence and overlap of selected cardiovascular co-morbidities among US adults with dyslipidemia, by lipid-lowering medication use status. Poster presented at the American College of Pharmacy annual meeting, October 13-17, 2007, Denver, Colorado
38. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-159 (Pubitemid 46269874)
39. Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708 (Pubitemid 46753568)
40. Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670-674 (Pubitemid 41608208)
41. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146